Breathe Well Live Well
|
Cytos to Secure up to CHF 37M to Advance Phase II Asthma Immunotherapy
Genetic Engineering News The funds will enable Cytos to conduct a global multicenter Phase IIb trial with its lead product CYT003-QbG10 in patients suffering from allergic asthma as well as to advance the rest of its pipeline. This transaction completes the financial … Cytos revives lead program in $40M financing deal with Amgen, venBio |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
AstraZeneca Pays Dynavax $3M to Speed Up Start of Asthma Drug Trials
Genetic Engineering News Dynavax Technologies will receive a $3 million payment from AstraZeneca to fund the initiation of clinical trials with their partnered asthma drug AZD 1419. The payment comes as part of the firms' amended collaboration to accelerate the start of … AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma Dynavax Technologies Corporation partners with AstraZeneca to advance AZD 1419 … |
View full post on asthma – Google News
|
Studies Link Asthma with Variations in IL6 Receptor Gene and Chromosome 11q13.5
Genetic Engineering News Genome-wide association studies focused on asthma risk genes have identified a variation in the interleukin-6 receptor (IL6R), and alterations at another site on chromosome 11q13.5 near the leucine-rich repeat containing 32 gene (LRRC32, also known as … |
View full post on asthma – Google News
 Stockopedia |
Sandoz Negotiates Expanded RoW Rights to Vectura's Asthma/COPD Drug VR315
Genetic Engineering News The Novartis generics business, Sandoz, negotiated expanded, rest-of-world (excluding the US) rights to Vectura's VR315 candidate combination therapy for asthma/COPD. Sandoz already holds European rights to the dry powder inhaler product. … Vectura Extends Novartis Deal For VR315 Lung Drug VECTURA GROUP PLC : VR315 RoW License Agreement Vectura signs up Sandoz for asthma drug in RoW; good results for ALK Abello … |
View full post on asthma – Google News
|
Researchers Claim LIGHT May Provide New Hope for Future Asthma Therapies
Genetic Engineering News Researchers claim the TNF protein family member LIGHT may represent a new target for halting the process of airway remodeling that leads to decreased lung function in asthma patients. A team headed by scientists at La Jolla Institute for Allergy and … |
View full post on asthma – Google News
|
LIGHT May Provide New Hope for Future Asthma Therapies, Researchers Claim
Genetic Engineering News Researchers claim the TNF protein family member LIGHT may represent a new target for halting the process of airway remodelling that leads to decreased lung function in asthma patients. A team headed by scientists at La Jolla Institute for Allergy and … La Jolla Institute identifies new therapeutic target for asthma, COPD and … |
View full post on asthma – Google News
|
Harvard Clinical Research Institute Initiates Comparative Effectiveness Study …
Genetic Engineering News Tiotropium) Study, the purpose of which is to investigate whether Black patients with asthma are more likely to experience adverse outcomes as a result of long-acting beta-agonist (LABA) therapy. The BELT study was funded by a grant from the Agency for … |
View full post on asthma – Google News
|
Revalesio to Present Research on the Anti-Inflammatory Effects of RNS60 in Asthma
Genetic Engineering News Revalesio Corporation announced today that research related to the use of RNS60, its novel anti-inflammatory, will be featured in two poster presentations at the Annual Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI) in San … |
View full post on asthma – Google News
|
Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma
Genetic Engineering News It intends to use the proceeds for working capital and general corporate purposes including its clinical trial program with bremelanotide for female sexual dysfunction (FSD), its PL-3994 programs for asthma, and for the preclinical development of … |
View full post on asthma – Google News
|
Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
Genetic Engineering News (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News